Spectral AI, Inc. (MDAIW) 股票分析

公司概述

Spectral AI, Inc. is an artificial intelligence company that focuses on predictive medical diagnostics within the United States market, utilizing its DeepView System to leverage proprietary AI algorithms for distinguishing between fully damaged, partially damaged, and healthy human tissue characteristics. Although the specific sector and industry classifications are not publicly disclosed in the available data, the company's operational focus on medical diagnostics places it within the broader healthcare technology landscape where AI-driven solutions aim to enhance diagnostic precision. The company operates with a workforce of 65 employees, generating trailing twelve-month revenue of $19.65 million, which reflects its current operational scale despite the absence of a listed market capitalization figure. The absence of a reported market cap suggests the company may be in a stage where valuation is derived through private market mechanisms or specific trading contexts rather than broad public market consensus, while the revenue figure indicates a mid-sized enterprise capability in a specialized niche.

财务健康

The company reported trailing twelve-month revenue of $19.65 million alongside a net income of -$7,571,000 and an EBITDA of -$8,532,000, revealing a significant gap between top-line revenue generation and bottom-line profitability that highlights substantial operational costs or investment phases not yet covered by earnings. Free cash flow stands at -$1,379,875, indicating that the company is currently consuming cash reserves rather than generating surplus liquidity, which implies a reliance on existing capital or external financing to sustain operations without immediate organic cash generation. Gross margin is reported at 45.4%, suggesting that the company retains a significant portion of revenue after direct costs, yet the operating margin of -54.9% and profit margin of -38.5% demonstrate that high overhead costs or strategic investments are severely erding pre-tax and net earnings. In terms of balance sheet composition, the company holds $15.39 million in cash against $10.09 million in debt, resulting in a debt-to-equity ratio that is not explicitly calculable due to missing equity data, though the absolute debt level is lower than cash holdings which suggests a conservative stance on leverage despite negative returns. The current ratio is 0.94, indicating that current assets fall short of current liabilities, which signals potential short-term liquidity pressure if the company cannot accelerate cash inflows or secure refinancing. Return on equity is not available for calculation, but return on assets is -32.1%, revealing that the company's asset base is currently generating negative returns and management effectiveness is challenged by the inability to convert asset investments into profitable outcomes.

估值评估

Trailing P/E and forward P/E ratios are both listed as not applicable, likely due to the lack of positive earnings, which prevents the calculation of traditional price-to-earnings metrics and implies that valuation must rely on alternative methodologies rather than earnings multiples. The price-to-book ratio is recorded at -3.08, a negative figure that typically arises in financial modeling when book value is negative or when the market price is compared against a negative equity base, suggesting a complex valuation environment where the market price may not align directly with traditional book value concepts. Price-to-sales and EV/EBITDA multiples are also not available, meaning that investors cannot utilize these alternative valuation metrics to assess the company's relative value against peers without relying solely on revenue or asset-based comparisons. The 52-week high is $0.59 and the 52-week low is $0.58, placing the stock in a very narrow trading range where the current price sits approximately 1.69% below the 52-week high and 1.72% above the 52-week low, indicating limited price movement over the past year. The beta value is 0.91, which indicates that the stock's price volatility is slightly lower than the broader market, suggesting that the share price tends to move in tandem with the overall market but with a dampened sensitivity to market-wide fluctuations.

Growth & Income

Revenue growth year-over-year is -46.3%, while earnings growth year-over-year is not available due to the company's negative earnings history, implying that the company is in a contraction phase regarding top-line sales and has not yet achieved a trajectory of earnings expansion that would allow for positive growth rate comparisons. As the company does not pay dividends, there is no dividend yield or payout ratio to evaluate for sustainability, meaning the company reinvests all available resources, including cash on hand, back into operations or research rather than distributing income to shareholders. The overall growth and income profile is characterized by significant revenue contraction and a complete absence of dividend distributions, reflecting a business model prioritized for long-term development or market capture rather than current profitability or income generation.